Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN) presented Phase 1 clinical data for LP-284 at the 25th LL&M Congress showing a confirmed complete metabolic response in a 41-year-old Grade 3 DLBCL patient who progressed after CAR-T and a CD3xCD20 bispecific. The patient achieved non-avid lesions after two 28-day cycles (IV on days 1, 8, 15).

Lantern highlighted LP-284's synthetic lethal TC-NER mechanism, preclinical synergy with rituximab, primarily Grade 1-2 adverse events, multiple FDA orphan drug designations, and composition-of-matter patents through 2039. Response durability data is expected by year-end 2025, and partnership discussions for combinations are underway.

Lantern Pharma (NASDAQ: LTRN) announced that company management will present at the ThinkEquity Conference on Thursday, October 30, 2025 at 11:30 a.m. ET at the Mandarin Oriental in New York City.

The presentation will be webcast and Lantern management will be available for one-on-one meetings during the conference. Webcast and conference registration links were provided for investor access.

Lantern Pharma (NASDAQ:LTRN) announced successful completion of its Phase 1a clinical trial for LP-184, achieving all primary endpoints with promising results. The trial demonstrated clinical benefit in 48% of evaluable patients at therapeutic dose levels, with a favorable safety profile suitable for both monotherapy and combinations.

Key highlights include disease control in multiple hard-to-treat tumors, particularly effective in patients with specific genetic mutations (CHK2, ATM, BRCA1, STK11/KEAP1). The recommended Phase 2 dose was established at 0.39 mg/kg, with the company planning targeted Phase 1b/2 trials in triple-negative breast cancer, non-small cell lung cancer, and bladder cancer - markets exceeding $6 billion annually.

Lantern Pharma (NASDAQ: LTRN) has successfully completed a Type C meeting with the FDA regarding its pediatric CNS cancer trial. The meeting provided crucial guidance for the trial design of LP-184/STAR-001, focusing on Atypical Teratoid Rhabdoid Tumor (ATRT) and other CNS cancers.

Key developments include FDA's confirmation for incorporating spironolactone as a combination agent and approval of a parallel cohort for ATRT patients. The program has received Rare Pediatric Disease Designation and Orphan Drug Designation. Lantern plans to submit an IND application amendment through its subsidiary, Starlight Therapeutics, with trial initiation targeted for Q1 2026.

Lantern Pharma (NASDAQ:LTRN) reported significant Q2 2025 achievements across its clinical pipeline and AI platform development. The company achieved major milestones including: successful completion of LP-184 Phase 1a enrollment with 65 patients, a remarkable complete response in the HARMONIC™ Trial for LP-300, and a complete metabolic response in an LP-284 trial patient.

Financial highlights include $15.9 million in cash and equivalents as of June 30, 2025, providing runway into June 2026. Q2 net loss was $4.33 million ($0.40 per share), improved from $4.96 million in Q2 2024. The company launched PredictBBB.ai™, an AI module for blood-brain barrier penetrability prediction, and enhanced its RADR® platform with new drug combination prediction capabilities.

Lantern Pharma (NASDAQ:LTRN) announced that its subsidiary, Starlight Therapeutics, received FDA clearance for its IND application to conduct a Phase Ib/2a clinical trial evaluating STAR-001 in combination with spironolactone for glioblastoma multiforme (GBM) patients. The trial will assess safety, tolerability, and preliminary efficacy in recurrent GBM patients.

STAR-001 is a brain-penetrant DNA-damaging agent that has received both FDA Orphan Drug and Fast Track Designations. The combination therapy leverages synthetic lethality, targeting approximately 60% of GBM cells that overexpress PTGR1. The global market opportunity for GBM treatment is estimated at $3-5 billion annually.

The company plans to commence the trial in late 2025 or early 2026, pending additional funding. A separate Phase 1a trial determining safety and dosing is expected to complete enrollment this quarter.

Lantern Pharma (NASDAQ:LTRN) has publicly released predictBBB.ai™, a groundbreaking AI module for predicting blood-brain barrier (BBB) permeability with 94% accuracy, 95% sensitivity, and 89% specificity. The platform leverages billions of data points across millions of compounds to address a critical pharmaceutical challenge, as only 2-6% of small-molecule drugs successfully cross the blood-brain barrier.

The technology currently holds five of the top eleven positions on the Therapeutic Data Commons Leaderboard. The BBB technologies market is projected to grow from $1.4 billion in 2023 to $9.85 billion by 2032. Lantern is implementing a freemium business model to accelerate adoption while creating pathways for strategic collaborations across the pharmaceutical ecosystem.

Lantern Pharma (NASDAQ: LTRN) has successfully completed targeted enrollment for its Phase 2 HARMONIC™ clinical trial in Japan, enrolling 10 patients ahead of schedule across five clinical sites, including the National Cancer Center Japan. The trial evaluates LP-300 in combination with carboplatin and pemetrexed for never-smoker patients with non-small cell lung cancer (NSCLC).

The trial has shown promising initial results, with an 86% clinical benefit rate and 43% objective response rate among the first seven U.S. patients, including one patient achieving a durable complete response lasting nearly two years. The global trial aims to enroll approximately 90 patients across multiple regions, targeting a market opportunity estimated at over $4 billion annually.

Japan represents a strategically important region with 35-40% of NSCLC cases occurring in never-smokers, compared to 15% in Western populations. Additional clinical data from both Asian and U.S. patient cohorts is expected by the end of Q3 2025.

Lantern Pharma (NASDAQ: LTRN) has appointed Dr. Lee T. Schalop to its Board of Directors. Dr. Schalop brings over 20 years of combined experience in biotechnology leadership and financial markets, with expertise in precision neurooncology and clinical development.

Dr. Schalop notably co-founded Oncoceutics, Inc., which was successfully sold to Chimerix Inc. for $450 million in 2021. At Oncoceutics, he served in various senior roles including CEO, and the company later became part of Jazz Pharmaceuticals in a $935 million acquisition in 2025.

This strategic appointment aligns with Lantern Pharma's focus on AI-driven oncology drug development and its CNS-focused pipeline through subsidiary Starlight Therapeutics. Dr. Schalop's expertise in clinical development and strategic transactions is expected to support the company's mission in transforming cancer drug discovery through AI and machine learning.